29, 2023 — Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45 percent compared to the traditional drug warfarin in the treatment of blood clots in the ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

A coroner has raised concerns that guidelines around blood thinners do not reflect the most "up to date international learning" following the death of a man. Brian Beer, 86, died at West Suffolk ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

In another new study, researchers suggest that the blood thinner heparin may delay the ... that could be targeted in the development of new drug therapies.” – Eric M. Reiman, MD The ...

Also Read: Bristol Myers’ $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting Opdivo sales increased 4% to $2.36 billion, and global sales ...

blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could ...

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...

He was less pleased to find out he’d need to take blood thinners twice a day – likely for the rest of his life – to reduce the risk of having a stroke. "I'm not used to taking all this stuff ...